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Introduction {#sec001}
============

*Salmonella enterica* subspecies *enterica* serovar Typhi and *Salmonella* Paratyphi A, B and C cause enteric fever, a systemic febrile illness that occurs only in humans. There are more than 2500 serovars of non-typhoidal Salmonella (NTS). NTS infects a variety of hosts and are frequently zoonotic in origin \[[@pntd.0007293.ref001]\]. It mainly causes self-limiting gastroenteritis in humans. NTS has also been recognized as a major cause of extra-intestinal invasive bacterial infection in young children and immunocompromised patients worldwide \[[@pntd.0007293.ref002],[@pntd.0007293.ref003]\]. It is a cause of severe bacteremia \[[@pntd.0007293.ref001]\]. It has been estimated that globally about 3.4 million cases of bacteremia due to NTS occur every year \[[@pntd.0007293.ref004]\]. The estimated worldwide mortality from NTS infection is 155,000 per year \[[@pntd.0007293.ref001]\]. Invasive NTS disease is considered to be an emerging and neglected tropical disease in Africa \[[@pntd.0007293.ref001]\].

Kuwait is a high-income subtropical country situated in the Middle East. It is neither a developing nor a developed country, but is a country in transition. There are no systemic studies of bacteremia due to NTS in Kuwait even though NTS is a major cause of diarrhea in Kuwait \[[@pntd.0007293.ref005],[@pntd.0007293.ref006]\]. Antimicrobial resistance is also a problem among diarrheal stool isolates of NTS in Kuwait \[[@pntd.0007293.ref007]\]. Also, there are no data on serovars of NTS causing infection in Kuwait. Therefore, the primary objective of the study was to assess the case-fraction of NTS bacteremia among bacteremia cases in two tertiary hospitals in Kuwait. The secondary objective was to determine the serovars of NTS isolates and their antibiotic susceptibilities. A study was conducted in two tertiary hospitals in Kuwait. We determined the serovars of NTS isolates and their antibiotic susceptibilities. Moreover, all isolates of *S*. Enteritidis and *S*. Typhimurium serovars were typed by pulsed-field gel electrophoresis (PFGE) to study their relatedness. In addition, selected isolates were subjected to whole genome sequencing for further characterization. We also compared our results with those from Africa. The results are presented in this communication.

Materials and methods {#sec002}
=====================

**Patients**. The only criterion for inclusion in the study was the isolation of a NTS from blood culture irrespective of any accompanying conditions and age. The indication for doing a blood culture was a suspicion of sepsis. Isolates were collected from Al Farwaniya hospital (which has pediatric and adult wards) from July 2013 until May 2016. The period of collection of isolates from Al Amiri hospital (which has neonatal, pediatric and adult wards) was from April 2013 until December 2015. The distance between the two hospitals is 26 km (16.2 miles). Al Farwaniya hospital is a 900-bed tertiary hospital which serves a population of 1.2 million people. Even though it serves both Kuwaitis and non-Kuwaitis, about 80% of the population served are non-Kuwaitis. Al Amiri hospital is a 418-bed tertiary hospital and it serves a population of 50,000 people. Although the hospital caters to both Kuwaitis and non-Kuwaitis, most of the people treated are Kuwaitis. All patients including diabetic patients and cancer patients have access to these hospitals, although for cancer treatment itself, there is a separate hospital. The patients included in our study were admitted in these hospitals, because of gastrointestinal symptoms and/or fever. Even though there are general guidelines for antimicrobial therapy, the antimicrobial therapy administered to patients in both hospitals was left to the discretion of attending physician. Antibiotics were given based on severity of infection, comorbidities and immune status of the patients.

Since typhoid is not endemic in Kuwait, typhoid vaccine is not offered to its residents. However, the vaccine is offered to residents travelling to high-risk areas.

**Blood culture.** Blood culture was done using BD BACTEC system (Becton Dickinson, MD, USA). From adults, 20 ml blood was drawn and 10 ml was inoculated into an aerobic bottle and 10 ml into an anaerobic bottle. From children, 1--5 ml of blood was drawn and inoculated into the aerobic bottle only. After inoculation of the bottle in the wards, they were immediately transported at ambient temperature to the hospital microbiology laboratory. Aerobic bottle signalling growth was subcultured on sheep blood agar, MacConkey agar and chocolate agar. The first two plates were incubated aerobically and the last plate in 5% CO2 atmosphere at 37°C for 24 h. Anaerobic bottle signaling growth was subcultured on brucella agar plate and the plate was incubated anaerobically at 37°C for 48 h. Identification of *Salmonella* and the initial antibiotic susceptibility were done from lactose non-fermenting colonies on MacConkey agar by Vitek 2 system (BioMerieux, Marcy l\'Etoile, France). For grouping of *Salmonella*, the colony was inoculated into triple sugar iron agar and if the reaction was suggestive of *Salmonella*, the growth was used in a slide agglutination test against *Salmonella* polyvalent and group-specific antisera (Denka Seiken, Tokyo, Japan). As soon as *Salmonella* was detected in blood culture, empirical antimicrobial therapy for the patient was initiated. Further identification of *Salmonella* and antibiotic susceptibility testing were done as described below.

Stool was cultured for *Salmonella* from all *Salmonella* blood culture-positive patients. When warranted, urine culture was done. Stool was inoculated onto MacConkey agar and *Salmonella*-*Shigella* agar (SSA) and enriched in selenite F broth. Selenite F broth was subcultured onto SSA after 20 h of incubation. When urinary tract infection was suspected, urine was cultured on CLED (cysteine, lysine, electrolyte-deficient) agar and blood agar. All plates were incubated for 20--24 h at 37°C. Suspected *Salmonell*a colonies were subjected to identification as above. Subcultures of Salmonella isolates on MacConkey agar plates from the hospital microbiology laboratories were sent to the reference laboratory at the Faculty of Medicine, Kuwait University, where further tests, listed below, were arranged or carried out.

**Typing of *Salmonella* isolates.** Internal fragments of seven housekeeping genes (*thrA, purE, sucA, hisD, aroC, hemD, dnaN*) were amplified by PCR \[[@pntd.0007293.ref008]\]. Sequences of the genes were trimmed to the required lengths (399--501 bps). Sequence types were assigned in accordance with the *Salmonella enterica* database, <http://mlst.ucc.ie/mlst/dbs/Senterica>. From sequence types, serovars were assigned according to the scheme of Achtman et al \[[@pntd.0007293.ref009]\]. Isolates belonging to *S*. Tyhimurium and *S*. Enteritidis serovars were further confirmed by specific PCR assays \[[@pntd.0007293.ref010]\].

**Antibiogram.** Antibiotic susceptibility test was carried out by E test (Biomerieux) and interpreted by the criteria laid down by Clinical and Laboratory Standards Institute (CLSI) \[[@pntd.0007293.ref011]\]. The breakpoints (μg/ml) (intermediate resistance, resistance) for various antibiotics were as follows: ciprofloxacin (0.12 to 0.5, ≥1), chloramphenicol (16, ≥32), trimethoprim/sulfamethoxazole (not applicable, ≥4), gentamicin (8, ≥16), tetracycline (8, ≥16), ampicillin (16, ≥32), ceftazidime (8, ≥16), cefotaxime (2, ≥4), ceftriaxone (2, ≥4), imipenem (2, ≥4), meropenem (2, ≥4) and piperacillin/tazobactam (32 to 64, ≥128). Resistant and intermediate-resistant minimum inhibitory concentrations were categorized as resistant in accordance with clinical practice.

When there was a necessity of testing resistance to other antibiotics (streptomycin, neomycin, carbenicillin, trimethoprim and sulfonamide), this was done by Kirby-Bauer disc diffusion test \[[@pntd.0007293.ref012]\].

Results were interpreted according to the criteria of CLSI \[[@pntd.0007293.ref013]\]. *Escherichia coli* ATCC 25922 strain was used as a quality control strain.

Extended spectrum β-lactamase (ESBL) production {#sec003}
-----------------------------------------------

**E test.** Isolates suspected of producing ESBL were tested for clavulanic-inhibitable ESBL production with E test ESBL strips--ESBL CT/CTL 16/1, ESBL TZ/TZL 32/4, ESBL PM/PML- as per manufacturer's instructions (BioMerieux).

**Vitek 2 test.** The Vitek 2 ESBL test (bioMérieux) is based on the simultaneous assessment of the antibacterial activity of cefepime, cefotaxime and ceftazidime, measured either alone or in the presence of clavulanate. This test relies on card wells containing 1.0 mg/L of cefepime, or 0.5 mg/L of cefotaxime or ceftazidime, either alone or associated with 10 or 4 mg/L of clavulanate, respectively. After inoculation, cards were introduced into the Vitek 2 machine, and for each antibiotic tested, turbidity was measured at regular intervals. The proportional reduction of growth in wells containing a cephalosporin combined with clavulanate was then compared with that achieved by the cephalosporin alone and was interpreted as ESBL- positive or--negative through a computerized expert system (Advanced Expert System) \[[@pntd.0007293.ref014]\].

**Detection of genes encoding ESBL.** PCR assays were performed to detect genes encoding *bla*~CTX-M~, *bla*~TEM~ and *bla*~SHV~ \[[@pntd.0007293.ref007]\] and *bla*~PSE-1~ \[[@pntd.0007293.ref015]\].

**AmpC disk test and modified three dimensional test (M3DT) for detection of AmpC β-latcamases.** This test was performed as described by Coskun et al \[[@pntd.0007293.ref016]\]. Enhanced growth of bacteria around blank disks and AmpC disk or intersected growth in the zone of inhibition was considered positive.

**Pulsed-field gel electrophoresis (PFGE).** PFGE was performed according to the CDC protocol (<http://www.cdc.gov/pulsenet/protocols.htm>) using *XbaI* restriction enzyme (Roche, Mannheim, Germany) and a CHEF-DR III PFGE system (Bio-Rad, Munich, Germany). *Salmonella* Braenderup strain H9812(ATCC BAA 664) was used as a reference strain. The bands were visualized under UV light with Gel DOC(Bio-Rad) and analyzed with Bionumerics software (Applied Maths NV, Belgium). Pairwise similarities between patterns were calculated by DICE's similarity coefficient. Clustering was based on unweighted pair-wise group method with averages (UPGMA) setting tolerance and optimization each at 1.5%.

**Whole genome sequencing (WGS).** Based on differences in banding patterns, *S*. Enteritidis and *S*. Typhimurium isolates were selected for whole genome sequencing. Sequencing libraries were prepared using the Nextera XT DNA sample preparation kit (Illumina, San Diego, CA, USA) and the sequence read data were produced on the Illumina NextSeq instrument (paired end, 150 base reads). Read data were submitted to the sequence read archive under project number PRJNA363099 (between 70x and 140x read depth coverage for each isolate). De novo assembly of the read data from each isolate was performed using MegaHit \[[@pntd.0007293.ref017]\]. The resulting draft genome sequences were used to derive MLST (MLST:<https://github.com/tseemann/mlst> PubMLST: <https://pubmlst.org/>).

Abricate (<https://github.com/tseemann/abricate>) was used to detect virulence genes (\[VFDB\]: \[[@pntd.0007293.ref018]\]). Antibiotic resistance gene profile was determined using Abricate and the Resfinder database \[[@pntd.0007293.ref019]\].

**Data management and analysis.** Data on NTS bacteremia were obtained from laboratory records. Patient charts were traced, and relevant information was extracted. Results of bacterial analysis including serovars, antibiogram and WGS data were linked to patient data and tabulated in the reference laboratory. This dataset was used for analysis as appropriate.

**Statistics.** The difference in the prevalence of resistance to antibiotics in the two hospitals was calculated by Chi square test. A P value of ≤0.05 was considered significant.

**Ethical approval.** Bacterial isolates studied were a part of the routine collection at the Enteric Microbiology Reference Laboratory, Kuwait University, for further studies and archiving. It was not possible to get informed consent of patients as the clinical data were retrospectively collected. No additional specimens were collected for this study and patient identity was kept anonymous. Therefore, a waiver for informed consent, and approval for the study were granted by the Ethics Committee of Ministry of Health, State of Kuwait (permit number 898/2018).

Results {#sec004}
=======

**NTS from blood culture.** The isolation of NTS from blood cultures of both hospitals is shown in [Fig 1](#pntd.0007293.g001){ref-type="fig"}. In Al Farwaniya hospital, 53,860 blood cultures were done and 3981 were positive for microorganisms. Of the positive cultures, 30 were positive for a non-typhoidal *Salmonella* serovar (0.75%). There were 13 different *Salmonella* serovars, but 50% of them belonged to *S*. Enteritidis (all sequence type \[ST\]11) and *S*. Typhimurium (all ST19). In Al Amiri hospital, 29, 036 blood cultures were done and 2,331 were positive for microorganisms. Of the positive cultures, 31 were positive for a non-typhoidal serovar (1.33%). There were 13 different serovars of *Salmonella* infecting the patients, but 19 isolates (61.3%) belonged to *S*. Enteritidis (all ST11) and *S*. Typhimurium (all ST19).

![Non-typhoidal *Salmonella* isolation from blood cultures of patients in Al Farwaniya and Al Amiri hospitals.\
A fraction (0.75--1.33%) belonged to non-typhoidal *Salmonella* (NTS).](pntd.0007293.g001){#pntd.0007293.g001}

Patient characteristics, *Salmonella* serovars isolated, response to therapy and patient outcome in Al Farwaniya and Al Amiri hospitals are presented in [Table 1](#pntd.0007293.t001){ref-type="table"}. Isolate numbers with suffix F are from Al Farwaniya hospital and those with suffix A are from Al Amiri hospital. Patients were both Kuwaitis and expatriates of many nationalities in both hospitals. Median age for all 61 patients was 58 y and 62.3% of patients were \>50 y old. Eight patients (13.1%) were children \<5 y old. Approximately 67% of patients had chronic diseases such as diabetes mellitus, cancer, blood disorder, kidney disease or lung disease. Forty patients (65.6%) had diarrhea and 26 of them (65%) had a *Salmonella* (identical to the corresponding blood isolate) cultured from the stool. Four of these 26 patients had also the corresponding *Salmonella* serovar cultured from the urine. One patient who had diarrhea did not have *Salmonella* cultured from the stool, but urine culture was positive for the corresponding blood isolate. None of the non-diarrheal patients had *Salmonella* cultured from the stool. Most patients responded to antibiotic therapy and were discharged. Many classes of antibiotics were used, but many received a cephalosporin. In addition, six patients (22A, 36A, 51A, 59A, 60A, 70A) received steroids. Only four patients died.

10.1371/journal.pntd.0007293.t001

###### Details of patients from Al Farwaniya hospital and Al Amiri hospital from whom *Salmonella* species were isolated from blood cultures.

![](pntd.0007293.t001){#pntd.0007293.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Isolate No.   Age   Gender   Nationality                                         Diagnosis                                                                              *Salmonella* species from blood   Diarrhea present   Isolation of *Salmonella* from sites other than\   Antibiotics given                                   Response to antibiotics   Outcome
                                                                                                                                                                                                                               [blood]{.ul}                                                                                                                     
  ------------- ----- -------- --------------------------------------------------- -------------------------------------------------------------------------------------- --------------------------------- ------------------ -------------------------------------------------- --------------------------------------------------- ------------------------- ---------------------------------------------------------
  1F            41    M        Indian                                              Abdominal pain                                                                         Livingston                        No                 No                                                 Cefotaxime, Metronidazole                           +ve                       Discharged

  2F            81    M        Kuwaiti                                             Cerebrovascular accident                                                               Unspeciated type 2641             No                 No                                                 Ceftriaxone                                         Uncertain                 Died

  3F            38    F        Kuwaiti                                             Diarrhea                                                                               Enteritidis                       Yes                No                                                 Cefotaxime                                          +ve                       Discharged

  5F            58    M        Indian                                              Abdominal pain, fever, vomiting                                                        Infantis                          No                 No                                                 Piperacillin/ tazobactam                            +ve                       Discharged

  7F            2.5   M        Kuwaiti                                             Intestinal obstruction, diarrhea                                                       Enteritidis                       Yes                No                                                 Ceftriaxone                                         Uncertain                 Transferred to surgical unit

  9F            5     M        Saudi                                               Abdominal pain, sickle cell anemia                                                     Typhimurium                       No                 No                                                 Cefotaxime                                          +ve                       Discharged

  10F           27    M        Indian                                              Pancytopenia                                                                           Enteritidis                       No                 No                                                 Ceftriaxone                                         Uncertain                 Transferred to Infect Dis Hospital for? HIV infection

  11F           \<1   F        Egyptian                                            Fever, bronchiolitis, diarrhea                                                         Typhimurium                       Yes                No                                                 Cefotaxime, gentamicin                              +ve                       Discharged

  12 F          72    M        Kuwaiti                                             Diabetes mellitus, ischemic heart disease, diarrhea, vomiting, fever                   Enteritidis                       Yes                No                                                 Piperacillin/ tazobactam, metronidazole             +ve                       Discharged

  13F           30    M        Filipino                                            Fever, diarrhea                                                                        Enteritidis                       Yes                No                                                 Cefotaxime, metronidazole                           +ve                       Discharged

  14F           45    M        Egyptian                                            Diabetes mellitus, chronic renal failure, fever                                        Livingston                        No                 No                                                 Cefotaxime                                          +ve                       Discharged

  15F           65    M        Pakistani                                           Diabetes mellitus, fever, jaundice                                                     Livingston                        No                 No                                                 Cefotaxime, clarithromycin                          +ve                       Discharged

  16F           2     F        Kuwaiti                                             Diarrhea                                                                               Minnesota                         Yes                No                                                 None, oral rehydration only                         +ve                       Discharged

  18F           56    M        Bangladeshi                                         Diabetes, eczema, diarrhea                                                             Kentucky                          Yes                No                                                 Ciprofloxacin                                       +ve                       Discharged

  19F           54    F        Iraqi                                               Diabetes, diarrhea                                                                     Typhimurium                       Yes                No                                                 Ciprofloxacin, metronidazole                        +ve                       Discharged

  46F           73    M        Kuwaiti                                             Diabetes mellitus, ischemic heart disease, fever, vomiting, diarrhea                   Typhimurium                       Yes                No                                                 Meropenem                                           +ve                       Discharged

  47F           76    M        Kuwaiti                                             Diabetes mellitus, colon cancer, acute kidney injury, loss of appetite                 Bareilly                          Yes                No                                                 Ceftriaxone                                         +ve                       Discharged

  48F           47    F        Kuwaiti                                             Sickle cell anemia, fever                                                              Enteritidis                       No                 No                                                 Ciprofloxacin                                       +ve                       Discharged

  52F           52    M        Egyptian                                            Colon cancer, weight loss                                                              Typhimurium                       No                 No                                                 Ciprofloxacin, amoxicillin/ clavulanic acid         +ve                       Discharged

  53F           70    F        Jordanian                                           Ischemic heart disease, chronic obstructive pulmonary disease, sinusitis               Enteritidis                       No                 No                                                 Ceftriaxone                                         Uncertain                 Transferred to neurosurgery for suspected brain abscess

  55F           24    F        Kuwaiti                                             Fever, vomiting, diarrhea                                                              Braenderup                        Yes                Stool                                              None, oral rehydration only                         +ve                       Discharged

  57F           47    F        Kuwaiti                                             Thalassemia, sickle cell anemia, upper respiratory infection, abdominal pain, chills   Poona                             No                 No                                                 Ceftriaxone, azithromycin                           +ve                       Discharged

  58F           46    M        Indian                                              Fever, thrombocytopenia, diarrhea                                                      Telaviv                           Yes                Stool                                              Piperacillin/ tazobactam, metronidazole             Uncertain                 Discharged against recommendation

  62F           65    M        Kuwaiti                                             Acute kidney injury, dehydration                                                       Typhimurium                       No                 No                                                 Meropenem, ceftriaxone                              +ve                       Discharged

  64F           1     M        Kuwaiti                                             Diarrhea, fever                                                                        Enteritidis                       Yes                Stool                                              Cefotaxime                                          +ve                       Discharged

  66F           59    M        Non- Kuwaiti[\*](#t001fn001){ref-type="table-fn"}   Diabetes mellitus, end-stage renal disease, sepsis                                     Poona                             No                 No                                                 No information                                      No information            No information

  68F           1     M        Non- Kuwaiti[\*](#t001fn001){ref-type="table-fn"}   Diarrhea                                                                               Anatum                            Yes                Stool                                              None, oral rehydration only                         +ve                       Discharged

  69F           66    M        Pakistani                                           Diabetes mellitus, cellulitis of thigh, diarrhea                                       Minnesota                         Yes                Stool                                              Piperacillin/ tazobactam, cefotaxime, clindamycin   +ve                       Discharged

  71F           59    M        Indian                                              Hyponatremia, ruptured aortic valve                                                    Enteritidis                       No                 No                                                 Cefotaxime                                          -ve                       Died

  74F           1     M        Kuwaiti                                             Diarrhea                                                                               Uganda                            Yes                No                                                 None, oral rehydration only                         +ve                       Discharged

  21A           79    F        Kuwaiti                                             Chronic kidney disease, liver chirrosis                                                Typhimurium                       Yes                No                                                 Ciprofloxacin                                       -ve                       Died

  22A           75    F        Kuwaiti                                             Diabetes mellitus, thrombocytopenia, Darriers disease                                  Enteritidis                       No                 No                                                 Ceftriaxone                                         +ve                       Discharged

  23A           62    M        Syrian                                              Diabetes mellitus, ischemic heart disease                                              Enteritidis                       Yes                Stool, urine                                       Ceftriaxone Metronidazole                           +ve                       Discharged

  24A           54    M        Kuwaiti                                             Diabetes mellitus, Ormond\'s disease, periaertitis                                     Typhimurium                       Yes                No                                                 Ciprofloxacin Ceftriaxone                           +ve                       Discharged

  25A           63    M        Kuwaiti                                             Acquired hemophilia                                                                    ST516                             Yes                Stool                                              Ceftriaxone                                         +ve                       Discharged

  26A           70    F        Kuwaiti                                             Diabetes mellitus                                                                      Enteritidis                       Yes                Stool                                              Ciprofloxacin                                       +ve                       Discharged

  27A           81    M        Kuwaiti                                             Diabetes mellitus, chronic kidney disease, liver cirrhosis                             Enteritidis                       Yes                Stool                                              Ceftriaxone, Meropenem                              +ve                       Discharged

  28A           85    M        Kuwaiti                                             Chronic kidney disease, ischemic heart disease, dyslipidemia                           ST27                              Yes                Stool                                              Ceftriaxone                                         +ve                       Discharged

  29A           72    M        Kuwaiti                                             Diabetes mellitus                                                                      Typhimurium                       Yes                Stool                                              Ceftriaxone                                         +ve                       Discharged

  30A           32    F        Kuwaiti                                             Ankylosing spondylitis, psoriasis                                                      Enteritidis                       No                 No                                                 Ceftriaxone Clindamycin                             +ve                       Discharged

  31A           83    M        Kuwaiti                                             Diarrhea                                                                               New type                          Yes                No                                                 Ceftriaxone                                         +ve                       Discharged

  32A           33    F        Egyptian                                            Sickle cell anemia, hepatitis C virus infection                                        Enteritidis                       Yes                Stool                                              No                                                  Uncertain                 Died within hours

  33A           69    M        Kuwaiti                                             Diabetes mellitus                                                                      Enteritidis                       Yes                Stool                                              Ciprofloxacin                                       +ve                       Discharged

  34A           65    F        Kuwaiti                                             Chronic kidney disease                                                                 Typhimurium                       No                 No                                                 Ceftriaxone                                         +ve                       Discharged

  35A           53    M        Pakistani                                           Acute kidney injury                                                                    Agona                             Yes                Stool                                              No                                                  +ve                       Discharged

  36A           52    M        Iranian                                             Chronic autoimmune skin disease, sepsis, acute kidney injury                           Typhimuriam                       Yes                Stool                                              Ciprofloxacin Meropenem Metronidazole               +ve                       Discharged

  37A           69    M        Kuwaiti                                             Diabetes mellitus, chronic kidney disease                                              Anatum                            Yes                Stool                                              Ciprofloxacin Meropenem                             +ve                       Discharged

  38A           2     M        Kuwaiti                                             Diarrhea                                                                               Enteritidis                       Yes                Stool                                              Ceftriaxone                                         +ve                       Discharged

  39A           73    M        Kuwaiti                                             Diabetes mellitus, skin disease, acute renal injury, sepsis                            Typhimurium                       No                 No                                                 Ceftriaxone Clindamycin                             +ve                       Discharged

  40A           54    M        Indian                                              Diabetes mellitus, ulcerative colitis                                                  Enteritidis                       Yes                Stool                                              Ciprofloxacin                                       +ve                       Discharged

  41A           80    F        Kuwaiti                                             Ischemic heart disease, toxic megacolon, dyslipidemia                                  Albany                            Yes                Stool                                              Ceftriaxone                                         +ve                       Discharged

  42A           58    F        Kuwaiti                                             Diabetes mellitus, chronic kidney disease                                              Typhimurium                       Yes                Stool                                              Ceftriaxone                                         +ve                       Discharged

  43A           73    M        Kuwaiti                                             Diabetes mellitus, dyslipidemia                                                        Newport                           Yes                Stool                                              Ciprofloxacin                                       +ve                       Discharged

  44A           75    M        Kuwaiti                                             Liver cirrhosis                                                                        Enteritidis                       Yes                Stool                                              Ciprofloxacin Ceftriaxone                           +ve                       Discharged

  45A           70    M        Kuwaiti                                             Diabetes mellitus, chronic kidney disease, fever                                       ST324/ST2606                      No                 No                                                 Ciprofloxacin                                       +ve                       Discharged

  49A           60    F        Kuwaiti                                             Chronic kidney disease                                                                 Minnesota                         Yes                Stool, urine                                       Ciprofloxacin Ceftriaxone                           +ve                       Discharged

  51A           45    M        Kuwaiti                                             Diabetes mellitus, Addison\'s disease, asthma                                          Typhimurium                       No                 Stool, urine                                       Ceftriaxone Clarithromycin                          +ve                       Discharged

  59A           36    M        Kuwaiti                                             Endstage renal disease                                                                 Bareilly                          Yes                Stool, urine                                       Ciprofloxacin                                       +ve                       Discharged

  60A           30    M        Kuwaiti                                             Lupus nephritis                                                                        Enteritidis                       Yes                Urine                                              Ciprofloxacin Metronidazole Amphotericin B          +ve                       Discharged

  61A           78    F        Kuwaiti                                             Diabetes mellitus, dyslipidemia, pneumonia, vomiting                                   Give                              No                 No                                                 Ciprofloxacin Cefotaxime                            +ve                       Discharged

  70A           36    F        Kuwaiti                                             Multiple sclerosis                                                                     Typhimurium                       Yes                No                                                 piperacillin/ Tazobactam                            +ve                       Discharged
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Non-Kuwaiti, but nationality uncertain

**Antibiogram.** The prevalence of resistance to all antibiotics was similar in both hospitals (P\>0.05 for all comparisons) ([S1A & S1B Table](#pntd.0007293.s003){ref-type="supplementary-material"}). Therefore, resistance for isolates from both hospitals was combined and is presented in [Table 2](#pntd.0007293.t002){ref-type="table"}. The prevalence of resistance to ampicillin, ciprofloxacin and tetracycline ranged between 36.1 to 50.8%. The prevalence of resistance to other antibiotics was either negligible or absent.

10.1371/journal.pntd.0007293.t002

###### Antibiotic susceptibility of non-typhoidal *Salmonella* isolated from blood cultures of 61 patients admitted in Al Farwaniya and Al Amiri hospitals, Kuwait.

![](pntd.0007293.t002){#pntd.0007293.t002g}

  Antibiotic                              Range (μg/ml)   MIC~50~   MIC~90~   No. (%) resistant
  --------------------------------------- --------------- --------- --------- -------------------
  Ampicillin (AMP)                        0.125 - ›256    2         ›256      22 (36.1)
  Ceftazidime (CAZ)                       0.094--32       0.38      2         5 (8.2)
  Cefotaxime (CTX)                        0.094--128      0.125     0.5       6 (9.8)
  Ceftriaxone (CRO)                       0.032--24       0.094     1.5       5 (8.2)
  Imipenem (IPM)                          0.032--1.5      0.19      0.5       0 (0.0)
  Meropenem(MEM)                          0.004--0.38     0.032     0.125     0 (0.0)
  Piperacillin/Tazobactam (TZP)           1.0--8          2         4         0 (0.0)
  Tetracycline (TET)                      1.5--256        8         256       31 (50.8)
  Gentamicin (GM)                         0.38--48        0.5       0.75      2 (3.3)
  Trimethoprim---Sulfamethoxazole (SXT)   0.047--32       0.25      32        9 (14.8)
  Chloramphenicol (CHL)                   0.032--256      6         16        7 (11.5)
  Ciprofloxacin (CIP)                     0.016--1.5      0.047     0.5       24 (39.3)

The resistance phenotypes in both hospitals are shown in [Table 3](#pntd.0007293.t003){ref-type="table"}. A total of 52 of 61 isolates (85. 2%) were resistant to one or more antibiotics tested. Of the resistant isolates, 30(60%) were either *S*. Typhimurium or *S*. Enteritidis. Among the 16 multi-resistant (resistant to three or more classes of antibiotics) isolates, 8 (50%) were either *S*. Typhimurium or *S*. Enteritidis. Fourteen isolates (23%) were resistant to a cephalosporin.

10.1371/journal.pntd.0007293.t003

###### Resistance phenotypes of non-typhoidal *Salmonella* isolates.
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  Resistance phenotype                      Number of isolates
  ----------------------------------------- --------------------
  Cip                                       1
  Amp                                       2
  Tet                                       16
  Cip, Tet                                  7
  Amp, Tet                                  3
  Tet, Chl                                  2
  Tet, Cro                                  1
  Tet, Ctx                                  1
  Cip, Sxt, Tet                             2
  Cip, Tet, Ctx                             1
  Cip, Chl, Tet                             1
  Amp, Caz, Ctx                             2
  Amp, Sxt, Tet                             2
  Amp, Tet, Caz                             1
  Amp, Ctx, Cro                             1
  Cip, Amp, Tet                             1
  Cip, Amp, Chl, Tet                        1
  Chl, Tet, Caz, Ctx, Cro                   1
  Cip, Amp, Chl, Sxt, Gent, Tet             1
  Cip, Amp, Chl, Sxt, Tet, Caz              1
  Cip, Chl, Tet, Caz, Ctx, Cro              1
  Cip, Amp, Chl, Tet, Caz, Ctx, Cro         2
  Cip, Amp, Chl, Sxt, Gent, Tet, Ctx, Cro   1

Cip: Ciprofloxacin, Amp: Ampicillin, Chl:Chloramphenicol, Cro: Ceftriaxone, Ctx: Cefotaxime

Sxt = Trimethoprim-sulphamethoxazole, Gen = Gentamicin, Tet = Tetracycline, Caz = Ceftazidime

**ESBL production.** One isolate (69F) from Al Farwaniya hospital was resistant to all three cephalosporins tested. Two isolates (45A and 49A) from Al Amiri hospital were resistant to all three cephalosporins. All three isolates were negative for clavulanic acid-inhibitable ESBL production by E test and for specific genes encoding ESBL, but were positive for ESBL production by both Vitek 2 test and E test. Two isolates (69F and 49A) were positive for AmpC test.

**PFGE.** The dendrogram of *S*. Enteritidis isolates from both Al Amiri and Al Farwaniya hospitals is shown in [Fig 2](#pntd.0007293.g002){ref-type="fig"}. There were three clusters--cluster 1 comprised isolates 12F, 53F, and 13F; cluster 2 comprised isolates 64F, 10F, 72F, 71F, 22A, 44A, 7F, 23A, 33A, 27A, 30A, 40A, and 38A; and cluster 3 comprised isolates 32A, 3F and 26A. Isolates 48F and 60A were outliers.

![PFGE dendrogram showing the relationship among *S*. Enteritidis.\
The similarities between isolates were evaluated using Dice coefficient and UPGMA clustering method.](pntd.0007293.g002){#pntd.0007293.g002}

The dendrogram of *S*. Typhimurium isolates from both Al Amiri and Al Farwaniya hospitals is shown in **[Fig 3](#pntd.0007293.g003){ref-type="fig"}.** There were three clusters--cluster 1 comprised of isolates 20F and 19F; cluster 2 comprised isolate 36A; cluster 3 comprised isolates 51A, 11F, 54F, 52F, 62F, and 46F; cluster 4 comprised isolates 34A, 21A, 70A, 39A, 42A and 29A. Isolate 36A was an outlier.

![PFGE dendrogram showing the relationship among *S*. Typhimurium.\
The similarities between isolates were evaluated using Dice coefficient and UPGMA clustering method.](pntd.0007293.g003){#pntd.0007293.g003}

**WGS.** Four *S*. Enteritidis isolates from Al Amiri hospital (23A, 32A, 38A, 60A) and two *S*. Enteritidis isolates from Al Farwaniya hospital (12F, 48F) were sequenced. Five *S*. Typhimurium isolates from Al Amiri hospital (21A, 51A, 34A, 29A, 36A) and four *S*. Typhimurium isolates from Al Farwaniya hospital (46F, 52F, 11F, 19F) were sequenced. These isolates belonged to different clusters by PFGE.

The phylogenetic relationship among the six *S*. Enteritidis isolates based on core genome sequence is shown in **[Fig 4](#pntd.0007293.g004){ref-type="fig"}.** The genome of *S*. Enteritidis strain P125109 was used as the reference genome sequence. More than 97% of the reference genome was present in the genomes of the six clinical *S*. Enteritidis isolates. The core genome contained 1999 sites that varied in the six clinical isolates. The pairwise distance was greatest (1670 SNPs \[single nucleotide polymorphisms\]) between isolates 60A and12F. There were three clusters formed by 12F, 23A & 38A; 32A; and 48F & 60A.

![An unrooted tree showing the inferred relationship between the six S. Enteritidis clinical isolates.\
The *S*. Enteritidis strain P125109 was used as the reference genome sequence for read mapping. More than 97% of the reference genome was included in the core genome derived for this set of isolates. The core genome contained 1,999 sites that varied in one or more of the clinical isolates. The tree was inferred using Fast Tree and the greatest pairwise distance between isolates is 1670 SNPs, e.g. between isolates 60A and 12F.](pntd.0007293.g004){#pntd.0007293.g004}

The phylogenetic relationship based on the core genomes of the six clinical *S*. Enteritidis isolates in relation to core genomes of 59 *S*. Enteritidis strains from different parts of the world for which there are closed genome sequences, is shown in **[S1 Fig](#pntd.0007293.s001){ref-type="supplementary-material"}.** The greatest pairwise distance of 1833 SNPs was found between isolate 48F and OLF-SE9-10012, a clam isolate of 2010 from Canada. There were a total of seven clusters and Kuwaiti isolates exhibited three clusters: 12F, 23A & 38A; 32A; and 48F & 60A. The details of genomes of 60 *S*. Enteritidis strains which were used for comparative analysis are given in [S2 Table](#pntd.0007293.s004){ref-type="supplementary-material"}.

The phylogenetic relationship of the nine *S*. Typhimurium isolates based on their core genome sequence is shown in **[Fig 5](#pntd.0007293.g005){ref-type="fig"}.** The genome of *S*. Typhimurium strain LT2 was used as the reference genome. More than 95% of the genome of the reference strain was contained in the genomes of the nine clinical *S*. Typhimurium isolates. The core genome contained 1979 sites that varied among the isolates. The greatest pairwise distance of 1017 SNPs was found between isolates 36A and 34A. Kuwaiti isolates formed five clusters: 11F, 51A &52F; 46F; 34A & 19F; 21A; 29A & 36A.

![An unrooted tree showing the inferred relationship between the nine *S*. Typhimurium clinical isolates.\
The *S*. Typhimurium strain LT2 was used as the reference genome sequence for read mapping. More than 95% of the reference genome was included in the core genome derived for this set of isolates. The core genome contained 1,979 sites that varied in one or more of the clinical isolates. The tree was inferred using Fast Tree and the greatest pairwise distance between isolates is 1,017 SNPs between isolates 36A and 34A.](pntd.0007293.g005){#pntd.0007293.g005}

The phylogenetic relationship of the nine *S*. Typhimurium isolates based on their core genomes in relation to 21 *S*. Typhimurium strains from different parts of the world whose closed genome sequences are known, is shown in **[S2 Fig](#pntd.0007293.s002){ref-type="supplementary-material"}.** The greatest pairwise distance of 1333 SNPs was found between isolates 22792 (a cormorant isolate of 2008 from Canada) and RM10961 (an isolate from an agricultural produce in the USA, whose isolation details are not known). There were a total of 10 clusters and Kuwait isolates formed four clusters: 19F; 34A; 21A, 29A & 36A; 46F, 11F, 51A & 52F. The details of genomes of 21 *S*. Typhimurium strains which were used for comparative analysis are shown in [S2 Table](#pntd.0007293.s004){ref-type="supplementary-material"}.

**Virulence genes.** The catalog of virulence genes identified in the whole genome-sequenced *S*. Enteritidis and *S*. Typhimurium is shown in [S3 Table](#pntd.0007293.s005){ref-type="supplementary-material"}. The organisms possessed genes encoding a variety of type III secretion system proteins that manipulate host cell transduction pathways and cellular processes to pathogen's advantage. Other genes included were those for chemotaxis and different fimbriae; anti- inflammatory effector genes for enhancing colonization; genes for resistance to antimicrobial peptides, mouse cecal colonization and prolonged shedding, cellular invasion, enteritis, fluid secretion etc. Of note are: *ste* gene (for spread and survival in host tissue), *sse* gene (for proliferation inside the macrophage and systemic infection in mice), *sodC1* gene (for resistance to phagocytosis), *rck* gene (for serum resistance) and *spv* genes (for proliferation inside the macrophages and late apoptosis and spread of infection).

**Antibiotic resistance genes.** Antimicrobial resistance genes were found in some of the whole genome- sequenced *S*. Typhimurium and *S*. Enteritidis isolates. These are shown in [Table 4](#pntd.0007293.t004){ref-type="table"}. Based on the presence of an antimicrobial resistance gene, resistance to the corresponding antibiotic was found in the isolate as indicated in the footnote to the Table. Even though *S*. Typhimurium isolate 34 A possessed *bla*~*CARB-2*~ gene, it was susceptible to imipenem and meropenem. *S*. Typhimurium isolate 34A resistant to ampicillin, chloramphenicol and tetracycline had corresponding resistance genes. The same isolate was ciprofloxacin- intermediate resistant and had a substitution of asparagine (N) for aspartic acid (D) at position 87 in the *gyrA* gene. Multi-resistant *S*. Typhimurium isolate 51A was ciprofloxacin-intermediate resistant and had a substitution of tyrosine (Y) for serine (S) at position 83 in the *gyrA* gene \[[@pntd.0007293.ref020]\]. *S*. Enteritidis isolates, 23A and 38A carried the ESBL gene, *bla*~TEM-1B~ and were resistant to ampicillin \[[@pntd.0007293.ref021]\]. Cephalosporin-intermediate-resistant isolates were not among the isolates that were subjected to whole genome sequencing.

10.1371/journal.pntd.0007293.t004

###### Antibiotic resistance genes in sequenced *S*. Enteritidis and *S*. Typhimurium isolates.

![](pntd.0007293.t004){#pntd.0007293.t004g}

  Gene[^a^](#t004fn001){ref-type="table-fn"}                     *S*. Enteritidis Isolates                   *S*. Typhimurium Isolates   GenBank   Resistance                                                                                      
  -------------------------------------------------------------- ------------------------------------------- --------------------------- --------- ------------ ----- ----- ----- ----- ------ ----- ------ ----- ------ ------ ------ ----------- ----------------------------
  ***aac(6\')-Iaa_1***                                           100[^b^](#t004fn002){ref-type="table-fn"}   100                         100       100          100   100   100   100   100    100   100    100   100    100    100    NC_003197   Aminoglycoside resistance
  ***aph(3\'\')-Ib_5***                                          \-[^c^](#t004fn003){ref-type="table-fn"}    \-                          \-        \-           \-    \-    \-    \-    100    \-    \-     \-    98.1   100    100    AF321551    Aminoglycoside resistance
  ***aph(3\')-Ia_1***                                            \-                                          \-                          \-        \-           \-    \-    \-    \-    100    \-    \-     \-    \-     \-     \-     V00359      Aminoglycoside resistance
  ***aph(6)-Id_1***                                              \-                                          \-                          \-        \-           \-    \-    \-    \-    100    \-    \-     \-    100    100    100    M28829      Aminoglycoside resistance
  ***blaCARB-2_1*** [^**d**^](#t004fn004){ref-type="table-fn"}   \-                                          \-                          \-        \-           \-    \-    \-    \-    \-     \-    100    \-    \-     \-     \-     M69058      Beta-lactam resistance
  ***blaTEM-1B_1*** [^**e**^](#t004fn005){ref-type="table-fn"}   \-                                          100                         \-        100          \-    \-    \-    \-    100    \-    \-     \-    \-     \-     \-     JF910132    Beta-lactam resistance
  ***dfrA5_1***                                                  \-                                          \-                          \-        \-           \-    \-    \-    \-    100    \-    \-     \-    \-     \-     \-     X12868      Trimethoprim resistance
  ***floR_2***                                                   \-                                          \-                          \-        \-           \-    \-    \-    \-    \-     \-    100    \-    \-     \-     \-     AF118107    Phenicol resistance
  ***sul2_2***                                                   \-                                          \-                          \-        \-           \-    \-    \-    \-    100    \-    \-     \-    100    100    100    AY034138    Sulphonamide resistance
  ***tet(A)\_6***                                                \-                                          \-                          \-        \-           \-    \-    \-    \-    97.8   \-    \-     \-    100    97.8   97.8   AF534183    Tetracycline resistance
  ***tet(G)\_2***                                                \-                                          \-                          \-        \-           \-    \-    \-    \-    \-     \-    100    \-    \-     \-     \-     AF133140    Tetracycline resistance
  ***gyrA* mutation**                                            \-                                          \-                          \-        \-           \-    \-    \-    \-    \-     \-    D87N   \-    \-     S83Y   \-     X78977      Fluoroquinolone resistance

^a^Gene symbol as per ResFinder database

^b^Percent gene coverage

^c^Negative for presence

^d^Alternate name: PSE-1, *blaP1b*

^e^Alternate name: Rbla TEM-1

Resistance to trimethoprim, sulphonamide and carbenicillin was tested by disk diffusion method. Resistance to other antibiotics was tested by E test

Discussion {#sec005}
==========

A small fraction (0.75--1.33%) of blood culture-positive isolates only accounted for NTS bacteremia in Kuwait. The prevalence of NTS bacteremia as a proportion of community-acquired bacteremia varies widely according to geographic areas. It was 8% in Southern Africa, 25% in Central Africa, 27% in East Africa, and 18% in Western Africa \[[@pntd.0007293.ref022]\]. In a multicenter study covering Indonesia, Thailand and Vietnam, the prevalence of NTS in individuals positive for any blood-stream bacterial infection was 27.5% among children, and 11.7% among adults \[[@pntd.0007293.ref023]\]. In a study in Bangladesh, the prevalence of NTS in blood culture was 0.16% \[[@pntd.0007293.ref024]\]. A Malaysian study found a prevalence rate of 16.2% with most of the cases occurring in children below 1 y of age \[[@pntd.0007293.ref025]\]. The risk factors contributing to NTS bacteremia are extremes of age, immunosuppressive therapy, and underlying comorbidities such as diabetes mellitus, cancer, cardiovascular diseases etc. that affect the immune system \[[@pntd.0007293.ref026]\]. In Africa, the risk factors for children are: sickle cell disease and malnutrition, and the risk factors not associated with age are malaria, anemia and human immunodeficiency virus infection \[[@pntd.0007293.ref022], [@pntd.0007293.ref026]--[@pntd.0007293.ref032]\]. In Kuwait too, the affected patients were either old people or children. The patients also suffered from comorbidities such as diabetes mellitus, cancer, blood disorders, lung diseases and kidney diseases. In our case series, 4 out of 61 patients died with a case- fatality rate (CFR) of 6.6%. This low CFR in our study may be attributed to prompt and appropriate therapy of our patients including better management of underlying diseases. CFR was 20.6% in Sub-Saharan Africa \[[@pntd.0007293.ref022]\]; 25% in Bangladesh \[[@pntd.0007293.ref024]\]; 33% in Israel \[[@pntd.0007293.ref033]\]; and 8.7% in Taiwan \[[@pntd.0007293.ref034]\]. A higher CFR of 40.5% was seen among NTS bacteremic patients with malignancy compared to 17.7% among NTS bacteremic patients without malignancy in Taiwan \[[@pntd.0007293.ref035]\]. In Al Farwaniya hospital, 16 patients (53.3%) had diarrhea, and of these, 5 patients (31.3%) had the same serovar of *Salmonella* as the one in blood culture isolated from the stool. There was an interval of 1--2 days between blood culture and stool culture. If blood culture of a patient was positive for a NTS, the patient was empirically treated with antibiotics during this interval. This antibiotic treatment would have affected the recovery of *Salmonella* in the stool culture of the patient. Approximately 5% of individuals with gastrointestinal illness caused by NTS will develop bacteremia \[[@pntd.0007293.ref036]\]. However, in primary NTS bacteremia, most of the patients do not develop diarrhea and NTS is also not cultured from stool \[[@pntd.0007293.ref037]\]. This suggested that a higher proportion of Kuwaiti patients with NTS bacteremia had gastrointestinal illness with the isolation of corresponding blood isolates from stools. Many different NTS serovars caused blood stream infection in Kuwaiti patients. However, 50--60% of the infections were due to *S*. Enteritidis and *S*. Typhimurium species in the two hospitals. Nonetheless, in Al Farwaniya hospital, most of the expatriate patients from South Asia and Southeast Asia had infection with neither of these serovars.

Although many serovars of NTS can cause blood stream infection, *S*. Enteritidis and *S*. Typhimurium serovars are the predominant serovars causing blood stream infection in many parts of the world \[[@pntd.0007293.ref022], [@pntd.0007293.ref029], [@pntd.0007293.ref038]--[@pntd.0007293.ref040]\]. NTS infection is usually zoonotic in origin contracted by contact with animals or consumption of contaminated water or food of animal origin \[[@pntd.0007293.ref041]\]. However, there is also evidence of person- to- person transmission \[[@pntd.0007293.ref042], [@pntd.0007293.ref043]\]. In the largely urban environment, coupled with the cultural context of Kuwait where pet animals such as dogs are a religious taboo, contact with animals is less likely, and the most likely routes are consumption of contaminated food and person- to- person contact.

Patients were treated with many antibiotic classes, but most were treated with a third-generation cephalosporin--ceftriaxone, cefotaxime or ceftazidime. Most patients responded to these antibiotics. The antibiotic response concurs with the susceptibility data (Tables [2](#pntd.0007293.t002){ref-type="table"} and [3](#pntd.0007293.t003){ref-type="table"}). ESBL production has been reported in NTS worldwide including in Kuwait \[[@pntd.0007293.ref007], [@pntd.0007293.ref044], [@pntd.0007293.ref045]\]. In the current study, three out of 13 cephalosporin- resistant isolates showed ESBL production. In two isolates, ESBL production may be mediated by AmpC. All the 13 resistant isolates were negative for specific genes. Resistance may also be due to other mechanisms such as an altered porin with decreased entry of the antibiotic into bacterial cell, with the bacteria showing intermediate susceptibility \[[@pntd.0007293.ref046], [@pntd.0007293.ref047]\]. A combination of tests needs to be done for the detection of ESBL production \[[@pntd.0007293.ref048]\]. Isolate 34A possessed the carbapenemase resistant gene, *bla*~*CARB-2_1*~, yet, it was susceptible to carbapenem. This concurs with a previous report \[[@pntd.0007293.ref015]\]. Most of the isolates were resistant to one or more antibiotics, and 26.2% were multidrug-resistant. Half of the multidrug-resistant isolates belonged to *S*. Typhimurium or *S*. Enteritidis. Drug resistance is a problem among NTS isolates in many parts of the world \[[@pntd.0007293.ref039], [@pntd.0007293.ref027], [@pntd.0007293.ref028], [@pntd.0007293.ref049], [@pntd.0007293.ref050], [@pntd.0007293.ref051], [@pntd.0007293.ref052]\]. Studies in African countries showed a higher prevalence of multidrug-resistant bacteria (40 to 100%) \[[@pntd.0007293.ref028], [@pntd.0007293.ref049]--[@pntd.0007293.ref052]\] than in our study.

We typed all NTS isolates by PFGE and some selected isolates by WGS. There were discrepancies between the two typing methods. This is not unexpected as approaches to typing are different in the two methods. Nevertheless, studies have shown that WGS is more discriminatory than traditional typing methods including PFGE \[[@pntd.0007293.ref053],[@pntd.0007293.ref054]\]. Moreover, WGS gives a near thorough sequence information of all genes present in the bacteria. In our series, the MLST of *S*. Typhimurium was ST19 and that of *S*. Enteritidis was ST11.

In Sub- Saharan Africa, the predominant ST of *S*. Typhimurium was ST313 \[[@pntd.0007293.ref055], [@pntd.0007293.ref056]\]. ST 19 was the predominant type found in both Europe and North America \[[@pntd.0007293.ref057]\]. ST11 and ST19 were the predominant types causing gastroenteritis in Qatar, another Middle Eastern country \[[@pntd.0007293.ref058]\]. ST19 was the predominant type in Iran being isolated from blood, urine and stool specimens \[[@pntd.0007293.ref059]\]. It was also the predominant ST found in China \[[@pntd.0007293.ref060]\]. *S*. Enteritidis ST11 causes diarrhea and blood stream infection world-wide. It caused blood stream infections from Mozambique \[[@pntd.0007293.ref061]\], Kenya \[[@pntd.0007293.ref055]\], and Vietnam \[[@pntd.0007293.ref062]\].

Sequencing of our NTS isolates showed that they carried a full complement of virulence genes. Of note are the presence of genes that contribute to systemic spread and survival in the blood stream---*ste* gene for spread and survival in the host tissue through multiplication in a membrane-bound compartment, SCV \[[@pntd.0007293.ref063]\], *sse* gene for survival and replication inside the macrophages via a type III secretory system\[[@pntd.0007293.ref064]\], *sodC1* gene for protection of bacteria against superoxide generated within phagocytes \[[@pntd.0007293.ref065]\], *rck* gene for serum resistance \[[@pntd.0007293.ref066]\], and *spv* genes for virulence of NTS to cause extra-intestinal disease by cytotoxicity and apoptosis of macrophages \[[@pntd.0007293.ref067]\].

Thus, our data showed that unlike in sub-Saharan Africa and some parts of Asia, there was only a low-case fraction of NTS isolated from blood cultures done at these two hospitals in Kuwait. From a public health point of view, these patients need to be protected from contracting NTS infection by provision of thoroughly cooked foods of animal origin, and a high standard of personal hygiene of caregivers. A significant proportion of our patients had gastrointestinal illness, and mortality was negligible. Similarities with other studies included the following: the patients affected were young or old; most patients had immunocompromising co- morbidities; an array of serovars of *Salmonella* caused blood stream infection, but most of the isolates were *S*. Typhimurium and *S*. Enteritidis; and drug resistance was a problem in the isolates, but most infections were treated with a third-generation cephalosporin with or without other antibiotics. Unlike other studies, we performed phylogenetic analysis of all *S*. Typhimurium or *S*. Enteritidis isolates by PFGE and some selected PFGE typed isolates by WGS. These two typing methods showed that the isolates showed closely related clusters. Phylogeny by core genome analysis showed a close relationship with *S*. Typhimurium and *S*. Enteritidis from other parts of the world. WGS showed that *S*. Typhimurium and *S*. Enteritidis had a complement of virulence genes mediating extra-intestinal infection and antibiotic resistance genes mostly corresponding to the resistance phenotypes.

Our study has several limitations since it is a hospital-based study and cases were diagnosed by blood culture. For hospitalization, there is a selection bias towards more severe cases and associated conditions. Hospitalized cases are not truly representative of community cases where a spectrum of severity of cases can occur, and because of this, community population at risk cannot be properly defined. Therefore, our findings cannot be extrapolated to a general population. Hospital records are not primarily designed for research purposes because of incomplete and unstandardized information and diagnostic variability between hospitals. Retrospective studies may have inferior level of evidence compared with prospective studies, and may be subject to confounding variables that may be present, but not measured. Moreover, temporal relationships are difficult to assess in retrospective studies. The concentration of NTS in blood is about 1 cfu per ml \[[@pntd.0007293.ref068]\]. Therefore, conventional blood culture and even polymerase chain reaction (PCR) method may not be sensitive enough to detect all true positive cases \[[@pntd.0007293.ref069]\]. This is prompting investigators to design more sensitive methods \[[@pntd.0007293.ref070]\].
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